Symposium and Training at the IOZK: Immunotherapy in Neuro-Oncology, Friday, September 6, 2019

Immunotherapies have established themselves next to surgery, radiation, and chemotherapy over the last few years. The application of immunotherapy in neuro-oncology faces specific challenges, but is also show great promise. 
On the occasion of opening its new GMP Laboratory, the IOZK will hold a scientific symposium with international speakers on the topic of “Immunotherapy in Neuro-Oncology”. We look forward to welcoming you.

Friday, September 6, 2019  | 10:00-18:00 | Steigenberger Hotel Köln | Habsburgerring 9-13 | 50674 Cologne

CME Points: 9 | The number of participants is limited. The fees for the symposium are 45,00 €.

Venues: Steigenberger Hotel Köln | Habsburgerring 9-13 | 50674 Cologne

GMP Laboratory: IOZK Immun-Onkologisches Zentrum Köln | Hohenstaufenring 30-32 | 50674 Cologne

To register, please complete the application form below and send it to us by fax, e-mail, or post. 

Download invitation (Pdf)

Download application form (Pdf)

Scientific Program


09:30 Registration

Venue Steigenberger Hotel Köln

10:00-10:15 Welcome

Dr. Wilfried Stücker  |  CEO und Head of the IOZK Group |  IOZK Immun-Onkologisches Zentrum Köln | Germany

Molecular detection of circulating tumor cells and characterization of therapy-related drug metabolizing genes

Dr. Lothar Prix | Laboratory diagnostics | LADR Laborzentrum Recklinghausen | Germany

Results against glioblastoma by Sitoiganap

Prof. Dr. Apostolos Stathopoulos | Chief Neurosurgeon | Euroclinic | Athens, Greece

Future developments of brain tumor vaccines

Prof. Dr. Matthias Eyrich | Pediatric Clinic | University Hospital Würzburg | Germany

Multimodal immunotherapy at IOZK

Stefaan Van Gool MD. PhD. | Translational Oncology | IOZK Immun-Onkologisches Zentrum Köln | Germany

Lunch and guided tour of the IOZK Clinical Unit and the IOZK GMP Laboratory

Venue: IOZK Center | Immun-Onkologisches Zentrum Köln | Hohenstaufenring 30–32, 50674 Cologne

Immuno-radiotherapy to prevent brain metastases from lung cancer

Prof. Dr. Dirk de Ruysscher | Radiation Oncologist | Maastricht University | The Netherlands

GlioVax: Dendritic cell vaccination therapy of glioblastoma

PD Dr. Rüdiger Sorg | Institute of Transplantation Diagnostics and Cell Therapeutics | Heinrich-Heine-University Düsseldorf | Germany

Oncolytic virus for pediatric brain tumors: from the bench to the clinic

Prof. Dr. Marta Alonso | Pediatric Clinic | Clinica Universidad Navarra | Pamplona, Spain

15:45-16:15 Coffee break
Update on clinical results from a cohort of GBM patients treated with autologous dendritic cells

Prof. Dr. Ricardo Díez Valle | Neurosurgery | Clinica Universidad Navarra | Pamplona, Spain

Immune monitoring of glioblastoma patients treated with dendritic cell immunotherapy

Prof. Dr. Serena Pellegatta | Molecular neuro-oncology | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Milan, Italy

The Pan Tum Detect blood test (Apo10, TKTL1) and current immunophenotyping to monitor the response to immunotherapy

Dr. Oliver Feyen | Laboratory diagnostics | IOZK Immun-Onkologisches Zentrum Köln | Germany

17:45-18:00 Closing remarks

Dr. Wilfried Stücker | CEO und Head of the IOZK Group | IOZK Immun-Onkologisches Zentrum Köln | Germany


This post is also available in: German Spanish